Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis

被引:302
作者
Chan, CT
Floras, JS
Miller, JA
Richardson, RMA
Pierratos, A
机构
[1] Toronto Gen Hosp, Dept Med, Div Nephrol, Univ Hlth Network, Toronto, ON M5G 1L7, Canada
[2] Mt Sinai Hosp & Univ Hlth Network, Dept Med, Div Cardiol, Toronto, ON, Canada
[3] Univ Toronto, Humber River Reg Hosp, Toronto, ON, Canada
关键词
daily hemodialysis; home hemodialysis; hypertension; extracellular fluid volume; blood pressure; end-stage renal disease;
D O I
10.1046/j.1523-1755.2002.00362.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Left ventricular hypertrophy (LVH) is an independent risk factor for mortality in the dialysis population. LVH has been attributed to several factors, including hypertension, excess extracellular fluid (ECF) volume, anemia and uremia. Nocturnal hemodialysis is a novel renal replacement therapy that appears to improve blood pressure control. Methods. This observational cohort study assessed the impact on LVH of conversion from conventional hemodialysis (CHD) to nocturnal hemodialysis (NHD). In 28 patients (mean age 44 +/- 7 years) receiving NHD for at least two years (mean duration 3.4 +/- 1.2 years), blood pressure (BP), hemoglobin (Hb), ECF volume (single-frequency bioelectrical impedance) and left ventricular mass index (LVMI) were determined before and after conversion. For comparison, 13 control patients (mean age 52 +/- 15 years) who remained on self-care home CHD for one year or more (mean duration 2.8 +/- 1.8 years) were studied also. Serial measurements of BP, Hb and LVMI were also obtained in this control group. Results. There were no significant differences between the two cohorts with respect to age, use of antihypertensive medications, Hb, BP or LVMI at baseline. After transfer from CHD to NHD, there were significant reductions in systolic, diastolic and pulse pressure (from 145 +/- 20 to 122 +/- 13 mm Hg, P < 0.001; from 84 +/- 15 to 74 +/- 12 mm Hg, P = 0.02; from 61 +/- 12 to 49 +/- 12 mm Hg, P = 0.002, respectively) and LVMI (from 147 +/- 42 to 114 +/- 40 g/m(2) , P = 0.004). There was also a significant reduction in the number of prescribed antihypertensive medications (from 1.8 to 0.3, P < 0.001) and an increase in Hb in the NHD cohort. Post-dialysis ECF volume did not change. LVMI correlated with systolic blood pressure (r = 0.6, P = 0.001) during nocturnal hemodialysis. There was no relationship between changes in LVMI and changes in BP or Hb. In contrast, there were no changes in BP, Hb or LVMI in the CHD cohort over the same time period. Conclusions. Reductions in BP with NHD are accompanied by regression of LVH.
引用
收藏
页码:2235 / 2239
页数:5
相关论文
共 30 条
[1]   Left ventricular hypertrophy in daily dialysis [J].
Buoncristiani, U ;
Fagugli, R ;
Ciao, G ;
Ciucci, A ;
Carobi, C ;
Quintaliani, G ;
Pasini, P .
MINERAL AND ELECTROLYTE METABOLISM, 1999, 25 (1-2) :90-94
[2]  
Charra B, 1996, NEPHROL DIAL TRANSPL, V11, P16
[3]   Blood pressure control in dialysis patients:: Importance of the lag phenomenon [J].
Charra, B ;
Bergström, J ;
Scribner, BH .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :720-724
[4]  
CHAZOT C, 1995, NEPHROL DIAL TRANSPL, V10, P831
[5]   ECHOCARDIOGRAPHIC DETERMINATION OF LEFT-VENTRICULAR MASS IN MAN - ANATOMIC VALIDATION OF METHOD [J].
DEVEREUX, RB ;
REICHEK, N .
CIRCULATION, 1977, 55 (04) :613-618
[6]   LEFT-VENTRICULAR HYPERTROPHY AND HYPERTENSION [J].
DEVEREUX, RB ;
DESIMONE, G ;
GANAU, A ;
KOREN, MJ ;
MENSAH, GA ;
ROMAN, MJ .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 1993, 15 (06) :1025-1032
[7]   ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure [J].
Dyadyk, AI ;
Bagriy, AE ;
Lebed, IA ;
Yarovaya, NF ;
Schukina, EV ;
Taradin, GG .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (05) :945-951
[8]   Short daily hemodialysis: Blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients [J].
Fagugli, RM ;
Reboldi, G ;
Quintaliani, G ;
Pasini, P ;
Ciao, G ;
Cicconi, B ;
Pasticci, F ;
Kaufman, JM ;
Buoncristiani, U .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (02) :371-376
[9]   CLINICAL AND ECHOCARDIOGRAPHIC DISEASE IN PATIENTS STARTING END-STAGE RENAL-DISEASE THERAPY [J].
FOLEY, RN ;
PARFREY, PS ;
HARNETT, JD ;
KENT, GM ;
MARTIN, CJ ;
MURRAY, DC ;
BARRE, PE .
KIDNEY INTERNATIONAL, 1995, 47 (01) :186-192
[10]   Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
KIDNEY INTERNATIONAL, 1996, 49 (05) :1379-1385